Engineering and Scientific International Journal (ESIJ) ISSN 2394-7187(Online) Volume 7, Issue 3, July – September 2020 ISSN 2394 - 7179 (Print) 78 DOI: 10.30726/esij/v7.i3.2020.73015 Formulation Development and Characterization of Targeted Drug Delivery System for Breast Cancer Rajkumari Thagele *1 , Mohan Lal Kori 2 1 Professor, NRI Institute of Research & Technology-Pharmacy, Bhopal, M.P., India 2 Principal, Vedica College of B.Pharmacy, RKDF University,Bhopal, M.P., India Abstract— Cancer is one among the leading causes of death worldwide. Cancer cells proliferate at much faster rate than the normal cells. The available traditional cancer chemotherapy is not essentially selective as it depends on the kinetics of the cell growth. 1 Breast cancer is common lethal cause of malignancy among women around all the countries. Early detection of breast cancer facilitates the diagnosis and treatment prior to metastasis. Despite remarkable development in new medicine findings and therapies for carcinoma during previous decades, no significant treatment methods are accessible for cancer- affected people with invasive and metastatic carcinoma. During this stage, the patients have less response to cancer therapy thanks to recurrence properties of cancer. Keywords — Wheat; Six Parameter Models; Gene Effects 1. Introduction The incident of carcinoma is increasing in India and also this is often the second commonest cancer in rural Indian females [2]. Breast cancer detection at early stage has treatment like surgical resection with removal of axillary lymph nodes, radiotherapy, chemotherapy and hormone therapy [3]. Several risk factors for BC are well documented; however, for the bulk of girls with BC, it's impossible to spot specific risk factors. Nevertheless, some risk reduction could be achieved with prevention. WHO promotes BC control within the context of comprehensive national cancer control programmes that are integrated into non-communicable diseases and other related problems [4]. Recent years have seen significant effort devoted to formulate therapeutic agents in biocompatible nanocomposites such as nanoparticles, nanocapsules, micellar systems and conjugates as drug delivery systems. Application of nanotechnology for diagnosis, monitoring, disease therapy, and control of biological systems was referred to as “nanomedicine”, and it has been receiving extensive attention over the past decade. Among these drug delivery systems, nanoparticles have received a considerable attention for the delivery of wide variety of drugs as well as biological macromolecules and vaccines. Nanotechnologies in general and nanoparticles in particular have revolutionalized the administration of medicines. Nanotecnology symbolize not only a miniaturization of larger objects but the preparation of nanomaterials with physical and chemical characteristics that differ from those of bulk materials, because they are on a nanometric scale. Depending upon the process used for the preparation of nanoparticles nanospheres (matrix type nanodevices) or nanaocapsules (reservoir type nanodevices) can be obtained [5]. Nanoparticles have been defined as submicron sized drug carriers, where the drug is either adsorbed on the surface or encapsulated within the particle. These nanoparticles can be prepared from natural and synthetic polymers that may or may not be biodegradable depending on their route of administration. the main advantages of nanoparticles is improved bioavailability by enhancing aqueous solubility, increasing resistance time within the body (increasing half-life for clearance/increasing specificity for its associated receptors and targeting drug to specific location within the body. This is why Nanoparticles are increasingly used in variety of applications that includes drug carrier systems and to pass organ barriers such as the blood–brain barrier, cell membrane, etc. The cellular uptake, biodistribution and circulating half-life are the key factors which are influenced by particle size of nanoparticles. Nanoparticles can also overcome the multiple drug resistance phenotype mediated by glycoprotein-P (P-gP), resulting in increased drug content inside the cells and because of this reason biodegradable nanoparticles have been widely studied. Therefore, particle size becomes a primary concern while formulating a nanoparticulate system. Moreover the particle size thus obtained should be uniform because more uniform the distribution of particles more consistent will be the biodistribution, cellular uptake and drug release [6, 7]. Oral administration of the non-steroidal anti estrogen like tamoxifen citrate is the treatment of choice for the patients with all stages of estrogen receptor (ER) - positive breast cancer. Antagonizing estrogen is popular treatment strategy because ER over expression is observed in about 70% of breast cancers, and about two-thirds of breast cancers in postmenopausal women are ER-positive. Oral tamoxifen citrate undergoes extensive hepatic metabolism and the subsequent biliary excretion of metabolites. Although the plasma antitumor concentration of 4-hydroxytamoxifen citrate are only about 2% of these of the parent compound